FR2677653A1 - Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. - Google Patents
Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. Download PDFInfo
- Publication number
- FR2677653A1 FR2677653A1 FR9107363A FR9107363A FR2677653A1 FR 2677653 A1 FR2677653 A1 FR 2677653A1 FR 9107363 A FR9107363 A FR 9107363A FR 9107363 A FR9107363 A FR 9107363A FR 2677653 A1 FR2677653 A1 FR 2677653A1
- Authority
- FR
- France
- Prior art keywords
- leu
- asp
- thr
- iid6
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 46
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- 102000007079 Peptide Fragments Human genes 0.000 title claims abstract description 45
- 108010033276 Peptide Fragments Proteins 0.000 title claims abstract description 45
- 206010003827 Autoimmune hepatitis Diseases 0.000 title claims abstract description 25
- 238000003745 diagnosis Methods 0.000 title claims abstract description 8
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title claims description 48
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title claims description 48
- 150000001413 amino acids Chemical class 0.000 claims abstract description 76
- 230000002788 anti-peptide Effects 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 11
- 229940098773 bovine serum albumin Drugs 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 239000013060 biological fluid Substances 0.000 claims description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- KHTIUAKJRUIEMA-HOUAVDHOSA-N Thr-Trp-Asp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 KHTIUAKJRUIEMA-HOUAVDHOSA-N 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- LGBVMDMZZFYSFW-HJWJTTGWSA-N Phe-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=CC=C1)N LGBVMDMZZFYSFW-HJWJTTGWSA-N 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000004989 spleen cell Anatomy 0.000 claims description 2
- 101000899479 Zea mays Trimethyltridecatetraene synthase Proteins 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 abstract description 8
- 108010052832 Cytochromes Proteins 0.000 abstract description 8
- 208000005176 Hepatitis C Diseases 0.000 abstract description 6
- 208000006454 hepatitis Diseases 0.000 abstract description 5
- 231100000283 hepatitis Toxicity 0.000 abstract description 5
- 238000003748 differential diagnosis Methods 0.000 abstract description 4
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 42
- 238000012360 testing method Methods 0.000 description 15
- 238000010276 construction Methods 0.000 description 13
- 101150053185 P450 gene Proteins 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 230000002529 anti-mitochondrial effect Effects 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- -1 9-fluorenylmethoxycarbonyl Chemical group 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 101000909129 Rattus norvegicus Cytochrome P450 2D26 Proteins 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 108700005364 rat Dbl Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9107363A FR2677653A1 (fr) | 1991-06-17 | 1991-06-17 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. |
| DE69229269T DE69229269T2 (de) | 1991-06-17 | 1992-06-16 | Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostik |
| CA002111672A CA2111672A1 (en) | 1991-06-17 | 1992-06-16 | Human p450 iid6 cytochrome-derived peptide fragments, anti peptide fragment antibodies, and applications thereof in the diagnosis of autoimmune hepatitis |
| AT92912543T ATE180512T1 (de) | 1991-06-17 | 1992-06-16 | Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostik |
| ES92912543T ES2133320T3 (es) | 1991-06-17 | 1992-06-16 | Fragmentos peptidicos procedentes del citocromo humano p450 iid6, anticuerpos antifragmentos peptidicos y sus aplicaciones en el diagnostico en la hepatitis autoinmune. |
| PCT/FR1992/000539 WO1992022656A1 (fr) | 1991-06-17 | 1992-06-16 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune |
| JP50076893A JP3284240B2 (ja) | 1991-06-17 | 1992-06-16 | ヒトチトクロームｐ４５０ｉｉｄ６由来ペプチド断片、抗ペプチド断片抗体、及びそれらの自己免疫性肝炎の診断における応用 |
| EP92912543A EP0589993B1 (fr) | 1991-06-17 | 1992-06-16 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune |
| US08/162,149 US5830667A (en) | 1991-06-17 | 1992-06-16 | Human P450 IID6 cytochrome-derived peptide fragments, anti-peptide fragment antibodies, applications thereof in the diagnosis of autoimmune hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9107363A FR2677653A1 (fr) | 1991-06-17 | 1991-06-17 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2677653A1 true FR2677653A1 (fr) | 1992-12-18 |
| FR2677653B1 FR2677653B1 (enExample) | 1995-04-14 |
Family
ID=9413909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9107363A Granted FR2677653A1 (fr) | 1991-06-17 | 1991-06-17 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5830667A (enExample) |
| EP (1) | EP0589993B1 (enExample) |
| JP (1) | JP3284240B2 (enExample) |
| AT (1) | ATE180512T1 (enExample) |
| CA (1) | CA2111672A1 (enExample) |
| DE (1) | DE69229269T2 (enExample) |
| ES (1) | ES2133320T3 (enExample) |
| FR (1) | FR2677653A1 (enExample) |
| WO (1) | WO1992022656A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985542A (en) * | 1996-05-20 | 1999-11-16 | Sumitomo Chemical Company, Limited | Diagnostic kit |
| DE19805815C1 (de) * | 1998-02-13 | 1999-11-11 | Ansgar W Lohse | Diagnostikum zum Erkennen der autoimmunen Hepatitis |
| DE19930933B4 (de) * | 1998-07-10 | 2005-05-25 | Imtec Immundiagnostika Gmbh | Verfahren zur Bestimmung von anti-LKM 1-Antikörpern |
| US6787303B1 (en) | 1999-04-01 | 2004-09-07 | Alton Ochsner Medical Foundation | Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis |
| CA2421680A1 (en) * | 2000-09-29 | 2002-04-04 | Merck & Co., Inc. | Antibodies for human cytochrome p450 2d6 |
| US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
| EP2454276A4 (en) * | 2008-07-17 | 2013-07-10 | Inter K Pty Ltd | THERAPEUTIC AGENTS |
| CN102955030A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体ana的试剂盒及其检测方法 |
| CN102707055A (zh) * | 2012-06-11 | 2012-10-03 | 郑州安图绿科生物工程有限公司 | 一种联合或单独检测自身免疫性肝病相关抗体的试剂盒及其检测方法 |
| CN102955027A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体抗lc-1抗体的试剂盒及其检测方法 |
| CN102955026A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体asma的试剂盒及其检测方法 |
| CR20230131A (es) | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| EP3477303A1 (en) | 2017-10-27 | 2019-05-01 | Medizinische Hochschule Hannover | Method and means for diagnosing autoimmune hepatitis using autoantibody markers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106726A (en) * | 1990-02-16 | 1992-04-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV |
-
1991
- 1991-06-17 FR FR9107363A patent/FR2677653A1/fr active Granted
-
1992
- 1992-06-16 EP EP92912543A patent/EP0589993B1/fr not_active Expired - Lifetime
- 1992-06-16 WO PCT/FR1992/000539 patent/WO1992022656A1/fr not_active Ceased
- 1992-06-16 DE DE69229269T patent/DE69229269T2/de not_active Expired - Fee Related
- 1992-06-16 ES ES92912543T patent/ES2133320T3/es not_active Expired - Lifetime
- 1992-06-16 US US08/162,149 patent/US5830667A/en not_active Expired - Lifetime
- 1992-06-16 CA CA002111672A patent/CA2111672A1/en not_active Abandoned
- 1992-06-16 JP JP50076893A patent/JP3284240B2/ja not_active Expired - Fee Related
- 1992-06-16 AT AT92912543T patent/ATE180512T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP3284240B2 (ja) | 2002-05-20 |
| EP0589993A1 (fr) | 1994-04-06 |
| JPH06510663A (ja) | 1994-12-01 |
| US5830667A (en) | 1998-11-03 |
| ATE180512T1 (de) | 1999-06-15 |
| ES2133320T3 (es) | 1999-09-16 |
| CA2111672A1 (en) | 1992-12-23 |
| DE69229269T2 (de) | 1999-11-11 |
| FR2677653B1 (enExample) | 1995-04-14 |
| EP0589993B1 (fr) | 1999-05-26 |
| WO1992022656A1 (fr) | 1992-12-23 |
| DE69229269D1 (de) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0423301B1 (fr) | Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a | |
| Lenzi et al. | Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. | |
| EP1527101B1 (fr) | Anticorps specifiques du probnp(1-108) et leur utilisation pour le diagnostic de l'insuffisance cardiaque | |
| EP0589993B1 (fr) | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune | |
| JPS63501716A (ja) | 合成ペプチドおよびａｉｄｓおよびａｒｃの診断ならびにワクチン注射へのその使用 | |
| Allain et al. | Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies | |
| BRPI0923544B1 (pt) | Uso de um anticorpo anti-idiótipo da linhagem celular dsm acc2939 e método para a determinação imunológica de um anticorpo contra o peptídeo beta amiloide em uma amostra | |
| WO1998008946A1 (fr) | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide | |
| Desai et al. | Structural relatedness of distinct determinants recognized by monoclonal antibody TP25. 99 on β2-microglobulin-associated and β2-microglobulin-free HLA class I heavy chains | |
| EP0569309B1 (fr) | Polypeptides de synthèse appartenant au virus de l'hépatite C (VHC) et utilisables notamment pour détecter ce dernier | |
| FR2773157A1 (fr) | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide | |
| WO1991012332A1 (fr) | Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite | |
| EP0667897B1 (fr) | Methode d'immunodosage specifique de la glutathion peroxydase plasmatique humaine | |
| EP0724016A1 (fr) | Polypeptides mimotopes de Toxoplasma gondii et applications | |
| FR2663034A1 (fr) | Peptides de l'antigene sm-d et leur utilisation notamment pour le diagnostic du lupus erythemateux dissemine. | |
| FR2612519A1 (fr) | Nouvelles fractions peptidiques inductrices d'anticorps protecteurs contre le virus de la leucemie bovine, procede pour l'obtention de telles fractions, leurs sequences codantes et vaccins realises a partir de ces fractions | |
| FR2682113A1 (fr) | Peptides issus de la proteine a de la ribonucleoproteine snrnp-u1 et leur utilisation pour le diagnostic de la connectivite mixte. | |
| EP0494825A1 (fr) | Peptides synthétiques dérivant de l'antigène HBc du virus de l'hépatite B | |
| Schlagel et al. | Immunological effects of an arginine side chain contaminating synthetically prepared peptides | |
| FR2848566A1 (fr) | Peptides epitopiques de l'enzyme thyroperoxydase, les compositions les contenant et leurs applications | |
| JP2705791B2 (ja) | Ａｉｄｓ関連病の検出のための合成抗原 | |
| FR2775690A1 (fr) | Anticorps monoclonal et utilisations pour detecter des antigenes de la proteine core de vhc | |
| EP0252787A1 (fr) | Polypeptides de surfaces cellulaires, isolés et purifiés, reconnus par les anticorps responsables de la pathogénie du lupus érythémateux disséminé (LED), leur méthode d'obtention et leur application au diagnostic du LED | |
| CA2459947A1 (fr) | Compositions et methodes pour le dosage de l'aa4rp | |
| FR2945291A1 (fr) | Anticorps biomarqueur et dispositif de diagnostic pour la detection de certaines maladies auto-immunes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20100226 |